PRADAXA® (PELLETS)

Drug Information Related Patent

Hold Company

BOEHRINGER INGELHEIM

Dosage and Administration

PELLETS;ORAL

Specification

EQ 20MG BASE/PACKET; EQ 30MG BASE/PACKET; EQ 40MG BASE/PACKET; EQ 50MG BASE/PACKET; EQ 110MG BASE/PACKET; EQ 150MG BASE/PACKET

Indication

PRADAXA® is indicated for the treatment of venous thromboembolic events in pediatric patients.

Use

Instructions for Use

API

DABIGATRAN ETEXILATE MESYLATE

API Structure

We Supply

DABIGATRAN ETEXILATE MESYLATE

Note:

In-house Standard
Facility GMP
DMF/CDE/USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7932273	2025/9/7
7932273*PED	2026/3/7

API Patent

Patent No	Expiration Date
7932273	2025/9/7
7932273*PED	2026/3/7

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION